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CD25
+ regulatory T cells (Tregs) are a T-cell subset endowed with the capacity to suppress immune responses to both self and foreign antigens. Although a specific Treg marker has not been identified as yet, Tregs do display a typical 'pattern' of a constitutively increased expression of several molecules/receptors including CD25, CTLA-4, CD122, GITR and FOXP3 [1] .
A growing number of experimental and clinical studies show that Tregs can induce transplantation tolerance by suppressing immune responses to allograft antigens [2] . In a murine transplantation model, indefinite vascularized allograft survival was associated with the expansion of recipient CD4 +
+ FOXP3 + Tregs [3, 4] , and the adoptive transfer of de novo generated donor alloantigen-specific Tregs resulted in specific suppression of donor skin allograft rejection [5] . In line with these findings are results of first clinical studies performed largely on renal allograft recipients, which confirm that Tregs can suppress immune responses to allograft antigens [6] . Moreover, there is emerging evidence that allograft function may correlate with the level of Tregs [7] . There is a real need to identify a specific marker of Tregs, which would allow the monitoring of this cell population in the human organism.
In view of their natural tolerogenic properties, Tregs are currently considered a potential means of inducing donorspecific tolerance in clinical transplantation [8] . However, in the context of a potential therapeutic use of Tregs, it needs to be considered that both their induction and suppressive functions can be considerably affected by immunosuppressive drugs, including cyclosporin A (CsA), which is a calcineurin inhibitor, and rapamycin (RAPA), which is an mTOR inhibitor [9] . While the majority of previous studies focused largely on the effects of CsA and RAPA on the suppressive capacity of isolated nTregs, we asked how these drugs affect Tregs of extrathymic origin. In particular, we evaluated how immunosuppressive drugs influence the alloantigen-triggered generation of human Tregs in vitro. Moreover, we determined the effects of both drugs on the suppressive activity of Tregs induced in the presence of either drug.
Methods

Isolation of cells
Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized blood of healthy donors by density-gradient centrifugation over Gradisol L (Aqua Medica, Łódź, Poland).
Primary two-way mixed lymphocyte reaction
PBMCs were resuspended at a concentration of 1×10 6 cells/ml in complete medium: RPMI-1640 (Biomed Lublin, Poland) containing 10% heat-inactivated fetal calf serum (FCS) (Gibco), 20mM L-glutamine (Gibco), 10μg/ml gentamycine (Biochemie) and 1M N-2-hydroxyethylpiperazine-N′-2-ethanesulphonic acid (HEPES) (Gibco). The cells of two individuals were mixed at a ratio of 1:1 for the two-way mixed lymphocyte reaction (MLR). The mixed cells were cultured in 24-well plates at 37°C for 6 days in 5% CO 2 with drugs: 20ng/ml rapamycine (Wyeth-Lederle, Novartis Pharma GmbH) or 200ng/ml cyclosporine A (Novartis) and without them.
Identification of Tregs by flow cytometry
To identify Tregs, allostimulated PBMCs from primary MLRs were stained with the following mAbs: anti-CD4 (PE or PerCP), anti-CD25 fluorescein isothiocyanate (FITC) or allophycocyanin (APC), anti-CTLA4 (PE), anti-CD122 (PE) and anti-GITR (APC) (all from Becton Dickinson). Isotype controls were cells stained with IgG1 conjugated with the respective fluorochromes. Intracellular staining of FOXP3 was performed using the anti PE-FOXP3 staining set (eBioscience) according to the manufacturer`s instructions. Flow cytometry was carried out on a FACS Calibur using Cell Quest software. Tregs induced in primary MLR in the absence of both drugs. Cells were cultured for 72h in 96-well plates in culture medium containing RPMI-1640 (Biomed Lublin) supplemented with 10% heat-inactivated FCS (Gibco), 20mM L-glutamine (Gibco), 10μg/ml gentamycine (Biochemie) and 1M HEPES (Gibco) at 37°C in 5% CO 2 . Subsequently, cells were stained with anti-CD4 Ab, which enabled the narrowing of the proliferation analysis to CD4 + T cells. Controls included cells which were not stimulated with anti-CD3 Ab. As additional control, Tregs were isolated stained with CFSE and stimulated with anti-CD3 Ab.
Isolation of Tregs from primary MLR cultures
Cytokine concentration measurement
Concentrations of TGF-β1 and IL-10 were measured in supernatants from the cocultures of anti-CD3 Ab-stimulated PBMCs with CD4 + CD25 + Tregs using enzyme-linked immunosorbent assay kits (BD Pharmingen) according to the manufacturer's instructions.
Statistical analysis
Data are presented as median and median absolute deviation (MAD). Statistical analyses were performed by the Kruskal-Wallis test and the Wilcoxon test. Differences were considered significant at P≤0.05.
Results
Induction of functional CD4 + CD25 + Tregs during two-way primary MLR To evaluate whether CsA or RAPA suppresses the induction of CD4 + CD25 + Tregs following PBMC allostimulation, we performed MLR assays in which these drugs were added to culture medium in separate cultures (final concentrations of 200 and 20ng/ml for CsA and RAPA, respectively). On day 6 of MLR, we analysed the percentages of CD4 + CD25 high T cells expressing FOXP3, CTLA-4, CD122 and GITR. We found that both CsA and RAPA significantly decreased the percentage of CD4 + CD25 high T cells compared with the control cultures, to which neither drug was added ( Figure 3A) . The reduction of the percentage of CD4 + CD25 high T cells was significantly larger when they were generated in the presence of CsA than in the presence of RAPA. Also, only CsA significantly re- + Tregs generated during two-way MLR in the presence of CsA or RAPA was measured by their capability to inhibit T cell receptor (TCR)-mediated proliferation of PBMCs. To that end, CD4 + CD25 + Tregs isolated from MLR on day 6 were mixed at a ratio of 1:1 with PBMCs. PBMC proliferation was triggered by anti-CD3 Ab. Using CSFE allowed the analysis of the intensity of the PBMC proliferative response and their percentage in cell culture after consecutive cell divisions. Staining with anti-CD4 Ab enabled us to restrict measurements of cell proliferation to the CD4 + T-cell subset. The proliferation of the anti-CD3 Ab-activated CD4 + T cells was intensive, while CD4 + CD25 + Tregs did not proliferate. Only Tregs generated in the presence of RAPA (Treg-Rapa) inhibited CD4 + T-cell proliferation, whereas those induced in the presence of CsA (TregCsA) or without drugs (Treg-control) failed to inhibit TCR-mediated CD4 + T-cell proliferation ( Figure 5 ). In Moreover, we measured the concentrations of TGF-β1 in cocultures of CD4 + CD25 + Tregs and anti-CD3 Ab-activated PBMCs. The concentrations of TGF-β1 were higher in cultures to which Tregs were added compared with the control cultures containing no Tregs (Figure 6 ). In particular, the concentration of TGF-β1 in cocultures of activated PBMCs and Treg-Rapa was significantly higher than that in cocultures of PBMCs and Tregs induced in the presence of CsA (Treg-CsA). The concentration of TGF-β1 observed when PBMCs were cultured with Treg-CsAwas comparable to that measured after culturing PBMCs with Treg-control. The highest concentration of IL-10 was found when activated PBMCs were cultured with Treg-control, whereas the concentration of this cytokine was lowest after culturing PBMCs with Treg-CsA (data not shown). 
Discussion
Severe side effects of immunosuppressive drugs resulting in graft failure have created a need to develop non-toxic, antigen-specific therapies promoting the induction of transplantation tolerance. A growing body of data shows that therapeutic protocols involving CD4 + CD25 + Tregs may allow the reduction of doses of immunosuppressive drugs and lead to the development of tolerance.
In this study, we evaluated the potential effects of two widely used immunosuppressive drugs, CsA and RAPA, on the induction and the suppressive functions of CD4 + CD25
+ Tregs in vitro. We found that cells displaying the phenotype and the suppressive activity of Tregs are indeed generated following the in vitro allostimulation of PBMCs. In our experiments, CD4 + CD25 high T cells induced during MLR had higher expressions of FOXP3, CTLA-4 and CD122 compared with activated T cells (CD4   +   CD25 low ), consistent with results obtained in other studies [10, 11] . CD4 + CD25
high T cells sorted after 6-day MLR cultures inhibited the proliferation of T cells in secondary MLR cocultures, which confirmed their suppressive capacity.
We showed that RAPA and CsA, which inhibit the activation of especially allospecific CD4 + T cells, can also influence both the induction and the suppressive capacity of CD4 + CD25 + Tregs generated during PBMC allostimulation. Although inhibiting the activities of both calcineurin (by CsA) and mTOR kinase (by RAPA) suppressed the generation of CD4 + CD25 + Tregs, this effect was more potent in cells cultured in the presence of CsA. Moreover, the expressions of FOXP3 and CTLA-4 (both of which are essential for the induction and the suppressive function of Tregs [11] ) in CD4 + CD25
+ Tregs induced in medium containing CsA were reduced to a greater degree.
RAPA, by inhibiting mTOR kinase, arrests the cell cycle in the G1 phase without inhibiting the production of IL-2 (a cytokine playing an important role in the generation and the activity of Tregs [12] ) and the expression of IL2R. Although most studies performed both in vitro and in vivo showed that RAPA suppresses T effector cell proliferation while inducing Treg proliferation and preserving their suppressive capacity [3, 4, 13] , our results are consistent with the findings of Valmori et al. who found that RAPA suppresses the proliferation of both CD4 + non-Treg T cells and CD4 + CD25 + Tregs. This effect was observed after a single in vitro stimulation and persisted after consecutive stimulations [14] . Moreover, Kopf et al. reported that while RAPA promoted TGF-β1-mediated Treg generation, the total number of generated Tregs might be decreased by RAPA in the concentration range of 1-100 ng/ml [15] . There are also some differences of opinion as to whether RAPA stimulates the proliferation of Tregs or rather induces them de novo. Long et al. showed that addition of RAPA to cultures resulted in an increase in the percentage of CD4 + CD25 high FOXP3 + T cells which did not result from selective FOXP3 + T-cell proliferation, but rather from their induction in the G0 phase following inadequate activation [12] . Bruno et al. found that PI3K, Akt and mTOR kinases regulate the de novo expression of FOXP3 in human CD4 + T cells when the TCR-mediated signal is inadequate or when the PI3K/Akt/mTOR pathway is inhibited [16] .
On the other hand, the inhibition of the induction and the suppressive activity of CD4 + CD25
+ Tregs by CsA may result from several different factors. First, CsA, by inhibiting calcineurin activity, blocks the induction of active transcription factor Nuclear factor of activated T-cells (NFAT). This leads to a decrease in IL-2 and IL-2R gene expression. As shown in earlier studies, the lack of IL-2 or its functional receptor blocked the generation of Tregs both in the thymus and in the periphery. Moreover, the inhibition of calcineurin restricts the access of nuclear factor for FOXP3. Recent findings show that FOXP3 controls the induction and the suppressive capacity of Tregs through the NFAT pathway. Furthermore, the active calcineurin pathway may be involved in transmitting TGF-β1 positive signal for the development and the activity of Tregs [17] . CsA inhibits the in vitro transcription of FOXP3 gene, while RAPA does not substantially affect it. Moreover, CsA decreases the expression of FOXP3 in natural Tregs [9] . Kopf et al. reported that CsA potently suppressed, while RAPA promoted, TGF-β-mediated generation of murine Tregs [15] .
In the present study, we also showed that both drugs affect the suppressive capacity of in vitro-generated Tregs. We found that the percentage of FOXP3 + Tregs expressing GITR was lower in cultures in which Tregs were induced in the presence of RAPA (Treg-Rapa) than in those to which CsA was added. In view of the fact that GITR is a negative regulator of Treg activity [18, 19] , Treg-Rapa should display a more potent suppressive activity than Treg-CsA. Indeed, Treg-Rapa significantly inhibited anti-CD3 Ab-triggered CD4 + T-cell proliferation, in contrast to Treg-CsA which did not exert this effect. This effect was likely cytokine dependent. TGF-β1 is essential for the induction of Tregs. It is also involved in Treg suppressive activity, especially during the induction of graft tolerance [8] . In our experiments, the concentration of TGF-β1 was higher in all cultures in which Tregs were present than in control cultures, to which no Tregs were added. TregRapa likely produced more TGF-β1 than control Tregs and Treg-CsA. The concentration of TGF-β1 in cultures with Treg-CsA was comparable to that in control cultures. These results suggest that Treg-RAPA retains, and even increases, its suppressive capacity. This was also reported by other investigators who showed a correlation between active suppression and TGF-β1 concentration in the peripheral blood of renal allograft recipients [20] .
It appears that RAPA and TGF-β1 can promote the induction of Tregs by independent mechanisms. Bruno et al. showed that FOXP3 expression and Treg generation can be induced by TGF-β1 or independently of this cytokine [16] . Gao et al. found that RAPA acts synergistically with TGF-β1 in inducing murine Tregs in vitro. However, the activity of RAPA is independent of TGF-β1 and cannot be replaced by higher concentrations of TGF-β1. These authors also showed that administration of RAPA to mice promoted the de novo generation of antigen-specific FOXP3 Tregs [5] . It was also found that the TGF-β1 signal and calcineurin activity are required for Treg generation [21, 22] . The role of TGF-β1 in Treg's suppressive activity has not been determined as yet. It is known, however, that neutralization of TGF-β1 does not adversely affect CD4 + CD25 + Treg activity [23] . Previous studies focused on the effects of RAPA and CsA on generation of Tregs and the suppressive capacity of natural Tregs. We showed that Tregs generated in the presence of immunosuppressive drugs display different levels of suppressive activity. These experimental settings mimic those occurring in patients who receive immunosuppressive drugs. Treg-Rapa inhibited anti-CD3 Ab-triggered CD4 + T-cell proliferation, while Treg-CsA did not exert this effect. This activity is likely mediated by TGF-β1.
Our results suggest beneficial effects of combining RAPA with Tregs. Such therapeutic protocol may promote the generation of functional Tregs, thereby facilitating the induction of transplantation tolerance.
